NICE Rejects Tecentriq For Small-Cell Lung Cancer In England
Uncertainties Remain Over Long-Term Effectiveness
Roche’s Tecentriq has been rejected by health technology assessment body NICE for use in small-cell lung cancer on the National Health Service. The move follows an earlier knockback for the drug in PD L1-positive triple-negative breast cancer.
You may also be interested in...
Hot on the heels of recommending Roche’s drug for triple negative breast cancer, HTA body NICE today said the product should also be used for the first-line treatment of extensive-stage small-cell lung cancer.
A series of decisions on anticancer drugs from the UK’s NICE will act as a reminder to drug developers excited by potential breakthroughs that health technology assessment has become an exacting filter for new medicines to pass through.
In top-line final Phase III results from KEYNOTE-604, Keytruda improves PFS but not OS when combined with chemotherapy for the first-line treatment of small-cell lung cancer.